Moderna Revenue 2017-2022 | MRNA

Moderna annual/quarterly revenue history and growth rate from 2017 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Moderna revenue for the quarter ending September 30, 2022 was $3.364B, a 32.3% decline year-over-year.
  • Moderna revenue for the twelve months ending September 30, 2022 was $21.390B, a 80.8% increase year-over-year.
  • Moderna annual revenue for 2021 was $18.471B, a 2200.25% increase from 2020.
  • Moderna annual revenue for 2020 was $0.803B, a 1238.33% increase from 2019.
  • Moderna annual revenue for 2019 was $0.06B, a 55.58% decline from 2018.
Moderna Annual Revenue
(Millions of US $)
2021 $18,471
2020 $803
2019 $60
2018 $135
2017 $206
2016 $108
Moderna Quarterly Revenue
(Millions of US $)
2022-09-30 $3,364
2022-06-30 $4,749
2022-03-31 $6,066
2021-12-31 $7,211
2021-09-30 $4,969
2021-06-30 $4,354
2021-03-31 $1,937
2020-12-31 $571
2020-09-30 $157
2020-06-30 $67
2020-03-31 $8
2019-12-31 $14
2019-09-30 $17
2019-06-30 $13
2019-03-31 $16
2018-12-31 $35
2018-09-30 $42
2018-06-30 $29
2018-03-31 $29
2017-12-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $65.718B $18.471B
Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.441B 9.68
GSK (GSK) United Kingdom $74.044B 9.78
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.308B 21.01
Ginkgo Bioworks Holdings (DNA) United States $3.880B 0.00
Myovant Sciences (MYOV) United Kingdom $2.617B 0.00
Arcus Biosciences (RCUS) United States $1.545B 23.20
Biohaven (BHVN) United States $1.265B 0.00
Emergent Biosolutions (EBS) United States $0.703B 5.53
ADC Therapeutics SA (ADCT) Switzerland $0.348B 0.00
Enzo Biochem (ENZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.066B 0.00
Gelesis Holdings (GLS) United States $0.025B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00